14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HQL vs THW: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, abrdn Life Sciences Investors (HQL) captures the overall head-to-head institutional edge over abrdn World Healthcare Fund (THW) on higher Unified Composite conviction (46.0/100 HOLD vs. 36.7/100 SELL) after splitting the core matrix 1–3 (led by composite factor balance), while THW wins 1–0 across the 6-pillar growth and valuation breakdown. HQL trades at $17.76 (N/M Forward P/E, N/A operating margin) versus THW at $12.91 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: HQL earns the overall head-to-head edge with a stronger Unified Composite Score (46.0/100 HOLD vs. THW 36.7/100 SELL) and 0.90β · 39% Vol risk profile, whereas THW leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile THW is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HQL vs THW. Trailing 12-month operating profitability (HQL N/A vs THW N/A) and valuation multiples (HQL N/M vs THW N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $510.6M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ HQL vs THW Key Questions & Quantitative Answers
As of Nov 16, 2026, abrdn Life Sciences Investors (HQL) captures the overall head-to-head institutional edge over abrdn World Healthcare Fund (THW) on higher Unified Composite conviction (46.0/100 HOLD vs. 36.7/100 SELL) after splitting the core matrix 1–3 (led by composite factor balance), while THW wins 1–0 across the 6-pillar growth and valuation breakdown. HQL trades at $17.76 (N/M Forward P/E, N/A operating margin) versus THW at $12.91 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: HQL earns the overall head-to-head edge with a stronger Unified Composite Score (46.0/100 HOLD vs. THW 36.7/100 SELL) and 0.90β · 39% Vol risk profile, whereas THW leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile THW is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
THW leads the Growth & Scale pillar: HQL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with THW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HQL generates N/A in USD-normalized revenue versus N/A for THW. In operating R&D and SG&A reinvestment, HQL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for THW.
HQL and THW trade at balanced relative valuation multiples. HQL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas THW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HQL (N/A ROE) versus THW (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, HQL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 39% Vol realized risk). By comparison, THW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 27% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.